Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Ischemia | Early Phase 1 | ClinicalTrials |
| Cataract; Macular Degeneration | Phase 3 | ClinicalTrials |
| Sepsis | Phase 3 | ClinicalTrials |
| Prostatic Neoplasms | Phase 1 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Phase 3 | ClinicalTrials |
| Cerebral Infarction; Ischemia; Stroke | Early Phase 1 | ClinicalTrials |
| Urinary Bladder Neoplasms | Phase 3 | ClinicalTrials |
| Myalgia | Phase 2/Phase 3 | ClinicalTrials |
| Urinary Bladder Neoplasms | Phase 3 | ClinicalTrials |
| Precancerous Conditions | Phase 3 | ClinicalTrials |
| Prostatic Neoplasms | Phase 3 | ClinicalTrials |
| Cardiovascular Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive | Phase 4 | ClinicalTrials |
| Tuberculosis | Phase 3 | ClinicalTrials |
| Chagas Disease; Heart Diseases | Phase 3 | ClinicalTrials |
| Congenital Abnormalities; Lymphangioma; Lymphatic Abnormalities | Phase 1 | ClinicalTrials |
| Adenomatous Polyps; Colorectal Neoplasms; Polyps; Precancerous Conditions | Phase 3 | ClinicalTrials |
CONTENTS